NCT03712397View on ClinicalTrials.gov

Nanoliposomal Irinotecan in Head & Neck and Esophagus After Prior Platinum-based Chemotherapy or Chemoradiotherapy

PHASE2CompletedINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

December 24, 2018

Primary Completion Date

December 31, 2022

Study Completion Date

December 31, 2022

Conditions
Head & Neck Cancer
Interventions
DRUG

nanoliposomal irinotecan

combination therapy of nal-IRI , leucovorin and 5-FU in sequence at day 1, every 14 days counted as one cycle

Trial Locations (4)

Unknown

China Medical University Hospital, Taichung

National Cheng Kung University Hospital, Tainan City

Taipei Veterans General Hospital, Taipei

Tri-Service General Hospital, Taipei

All Listed Sponsors
collaborator

China Medical University Hospital

OTHER

collaborator

Tri-Service General Hospital

OTHER

collaborator

Taipei Veterans General Hospital, Taiwan

OTHER_GOV

collaborator

National Cheng-Kung University Hospital

OTHER

lead

National Health Research Institutes, Taiwan

OTHER

NCT03712397 - Nanoliposomal Irinotecan in Head & Neck and Esophagus After Prior Platinum-based Chemotherapy or Chemoradiotherapy | Biotech Hunter | Biotech Hunter